Drawing for Serial No. 79404163

USPTO serial 79404163

Serial No. 79404163

Reviewed by CopyMark Law Group

Reg. 8016754Status 700Registered
Filing date
Status date
Registration date
Nov 11, 2025
Examiner
RIBAUDO, MICHELLE RACHEL
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79404163?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—
009Downloadable software for the facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields; Downloadable software in the nature of a mobile application for facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields.ACTIVE—
010Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for the diagnosis, prevention and treatment of hematology diseases and disorders; medical apparatus and instruments for use in tissue and organ transplantation surgery; medical apparatus and instruments for the diagnosis, prevention and treatment of eye diseases and conditions; medical apparatus and instruments for the diagnosis, prevention and treatment of heart rhythm disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of immune system related diseases and disorders.ACTIVE—
041Providing on-line journals, namely, blogs in the medical, pharmaceutical and health fields.ACTIVE—
042Medical and pharmaceutical research services; Pharmaceutical research and development.ACTIVE—
044Providing information in the fields of medicine and health via a website; Providing information about the diagnostic, prophylactic and therapeutic properties of medicines via a website; providing information in the medical field and information in the field of diagnostic, prophylactic and therapeutic properties of medicines; providing health information; providing patients with information in the medical field.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 11, 2026FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
May 25, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 25, 2026FIMPFINAL DISPOSITION PROCESSED—
Feb 26, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Feb 11, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 11, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 11, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Nov 11, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Nov 11, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 23, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 23, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 17, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 29, 2025RFNTREFUSAL PROCESSED BY IB—
Aug 27, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 20, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 20, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 20, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 8, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 7, 2025RFRRREFUSAL PROCESSED BY MPU—
Aug 6, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 5, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 13, 2024RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Nov 7, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 6, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 4, 2024DOCKASSIGNED TO EXAMINER—
Oct 11, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Oct 11, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 11, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 11, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 11, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 7, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 7, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 19, 2024LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Sep 12, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance